Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - Aligos Therapeutics, Inc. | algs-ex321_6.htm |
EX-31.2 - EX-31.2 - Aligos Therapeutics, Inc. | algs-ex312_8.htm |
EX-31.1 - EX-31.1 - Aligos Therapeutics, Inc. | algs-ex311_9.htm |
EX-10.4 - EX-10.4 - Aligos Therapeutics, Inc. | algs-ex104_182.htm |
EX-10.3 - EX-10.3 - Aligos Therapeutics, Inc. | algs-ex103_277.htm |
EX-10.2 - EX-10.2 - Aligos Therapeutics, Inc. | algs-ex102_183.htm |
EX-10.1 - EX-10.1 - Aligos Therapeutics, Inc. | algs-ex101_184.htm |
10-Q - 10-Q - Aligos Therapeutics, Inc. | algs-10q_20210331.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aligos Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: May 10, 2021 |
|
By: |
/s/ Lesley Ann Calhoun |
|
|
|
Lesley Ann Calhoun |
|
|
|
Chief Financial Officer |